z-logo
open-access-imgOpen Access
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis
Author(s) -
Stephen C. Aronoff,
Jeffrey D. Klinger
Publication year - 1984
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.25.2.279
Subject(s) - amikacin , ticarcillin , aztreonam , aminoglycoside , tobramycin , piperacillin , cystic fibrosis , microbiology and biotechnology , pseudomonas aeruginosa , medicine , antibiotics , biology , gentamicin , antibiotic resistance , bacteria , imipenem , genetics
Amikacin, combined with aztreonam, piperacillin, or ticarcillin, synergistically inhibited amikacin-resistant sputum isolates of Pseudomonas aeruginosa and P. cepacia from children with cystic fibrosis. Ticarcillin-amikacin was the least active combination. Aminoglycoside resistance should not preclude the use of beta-lactam-aminoglycoside combinations in the treatment of pulmonary infections in cystic fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here